The Top 5 Biosimilars Articles for the Week of August 13

August 17, 2018

The Center for Biosimilars® recaps the top news for the week of August 13, 2018.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of August 13.

Number 5: AbbVie has filed suit against biosimilar developer Sandoz over its proposed Humira biosimilar.

Number 4: Fifty-two-week results of a phase 3 study, which included a switch from Humira to SB5, show that switching led to no change in treatment-emergent adverse events.

Number 3: The clinical director of Ireland’s health technology assessment body has called for all new patients to start treatment with biosimilars rather than with reference products.

Number 2: The Federal Trade Commission has called on the FDA to use its authority to foster biosimilar competition.

Number 1: CVS Caremark says that it will use data from the Institute for Clinical and Economic Review in making coverage decisions.

Finally, last week, our e-newsletter asked whether you think that the United States should follow Australia’s lead in using “uptake drivers” for biosimilars.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.